Day: October 9, 2024

KUALA LUMPUR, Malaysia, Oct. 09, 2024 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (Frankfurt: H0T) (“VCI Global” or the “Company”), through its subsidiary, V Gallant Sdn Bhd (“V-Gallant”), is offering end-to-end AI computing solutions to enterprises by integrating next-generation AI servers equipped with NVIDIA H200 Tensor Core GPUs and AI software such as Large Language Models (LLMs) and automated machine learning platforms. Beyond seamless integration, enterprises can enhance operational efficiency by optimizing computing power distribution, improving data flow, and task automation. V-Gallant collaborates with leading server manufacturers and solution providers to empower organizations to fully leverage the latest advancements in generative AI, accelerating AI training and inference applications. By integrating AI computing...

— Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital — BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approximately $110 million private placement financing, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement to finance the initiation of a Phase 2b trial in pulmonary arterial hypertension (“PAH”) and for general corporate purposes. The private placement...

Increased Utilization and Downloads of My Agent Account Reflect Growing Adoption of La Rosa’s Proprietary Platform by its Agents Celebration, FL, Oct. 09, 2024 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for six agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced the launch of My Agent Account version 3.0, a significant upgrade to its proprietary platform, which now includes a new module specifically designed for property management disbursements. This update is expected to improve operational efficiency for agents across the Company. My Agent Account, La Rosa’s proprietary platform, was designed to empower agents with a comprehensive suite of tools and resources. Serving as a centralized hub, it enables agents...

-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that it has initiated its rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA), seeking full approval for deramiocel to treat all patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. “This announcement marks an important step in the U.S. regulatory process towards a potential Biologics License Application approval of deramiocel for the treatment of DMD,” said Linda Marbán, Ph.D., Chief Executive Officer of Capricor....

Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities BERKELEY HEIGHTS, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent will be presented as a poster at the 2024 AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”), to be held in Barcelona, Spain (October 23-25, 2024). The patients were enrolled in the biomarker-enriched, Cohort 8...

Nasdaq Copenhagen                                                                                    Nikolaj Plads 6 DK-1067 Copenhagen K    Copenhagen, 9 October 2024 ANNOUNCEMENT no. 12/2024 CeMat A/S acquires right of perpetual usufruct to land plot in Bielany, Warsaw CeMat A/S is pleased to announce that it has obtained a binding decision confirming its acquisition by law of the right of perpetual usufruct (RPU) to 75% of the shares in an undeveloped plot of land on Wólczyńska Street, in the Bielany district of Warsaw. The decision relates to a land plot covering a total area of 6,720 sqm, and grants the company the right of perpetual usufruct until 2089. This binding decision provides the legal basis for registering the RPU in the land and mortgage register. The acquired plot is currently being used by the company for internal...

Almere, the Netherlands October 9, 2024 ASM International N.V. (Euronext Amsterdam: ASM) will report its third quarter 2024 financial results at approximately 6:00 p.m. CET on Tuesday, October 29, 2024. ASM will host the quarterly earnings conference call and webcast on Wednesday, October 30, 2024, at 3:00 p.m. CET. Conference-call participants should pre-register using this link to receive the dial-in numbers, passcode and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay will be accessible at this link. About ASM International ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia....

Press ReleaseNokia and Furukawa Electric LatAm expand partnership in Brazil to reach data center marketSecurity and automation designed for the AI era are focus of new phase of partnership, designed for data centers of all sizes in Brazil. Solutions immediately available for Brazilian market bring together Nokia’s modern data center automation platform and Nokia DDoS attack detection and mitigation software. Existing partnership between the companies to commercialize advanced passive optical network (POL) technologies continues throughout Latin America.9 October 2024São Paulo, Brazil – Nokia and Furukawa Electric LatAm today announced they have expanded their partnership to immediately bring high-performance solutions in data center automation to Brazil. Partners since 2022, the two companies will also continue to offer advanced...

SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that it will be participating in the Maxim Group 2024 Virtual Healthcare Summit being held October 15-17, 2024. Gregory D. Gorgas, CEO of Artelo Biosciences, will be joining Jason McCarthy, Maxim’s Senior MD and Head of Biotechnology Research analyst, in a fireside chat on Wednesday, October 16, 2024 at 4:00 p.m. ET. The fireside chat will be available for webcast by registering at https://m-vest.com/events/healthcare-10152024. About Artelo BiosciencesArtelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the...